News 18.12.2023 Zurich-Schlieren, Switzerland, December 18, 2023. Proteomedix AG, a spin-out of ETH Zurich is a Swiss diagnostics company committed to advance prostate cancer care, today announced it has been acquired by US-based, NASDAQ-listed Blue Water Biotech Inc. (NASDAQ: BWV) in a share exchange transaction. The merged entity with the new name...
News 16.12.2023 Zürich, Switzerland, December 14, 2023 InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, is proud to announce the appointment of Paul Clémençon, MBA as the new Chief Business Officer (CBO), further strengthening its Executive team. Since joining the company in 2022 as the Head of Business Development, Paul has...
News 11.12.2023 Saint-Prex and Schlieren, Switzerland– 11 December, 2023 – Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring with exclusive rights to develop, manufacture and commercialize next generation microbiome-based therapeutics within...
News 11.12.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its...
News 06.12.2023 Washington, D.C., Zürich, Switzerland The Physicians Committee for Responsible Medicine, a nonprofit that advances human-based science, and InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, are pleased to announce the winners of the HUMAIN Award 2023 (Human Advanced In Vitro Model Initiative). The award recognizes researchers working to expand access to and accelerate the...